Endovascular Repair for the Descending Thoracic Aorta (ERRATA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02376998 |
Recruitment Status :
Completed
First Posted : March 3, 2015
Results First Posted : October 7, 2016
Last Update Posted : October 7, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aorta Thoracic; Traumatic Rupture | Device: Valiant™ endoluminal procedure | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Endovascular Repair for Acute Traumatic Transection of the Descending Thoracic Aorta |
Study Start Date : | November 2002 |
Actual Primary Completion Date : | November 2014 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Valiant™ endoluminal procedure
Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
|
Device: Valiant™ endoluminal procedure
Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows: The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions. After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak. |
- Number of Participants With Major Adverse Events [ Time Frame: from hospital discharge to 1 month after the procedure ]Evaluation of mortality, renal failure, cerebrovascular accident.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with a diagnosis of acute transection of thoracic aorta;
- a time frame range from trauma of 1-10 hours.
Exclusion Criteria:
- Patients who do not fall into the above categories
Responsible Party: | Prof. Raffaele Serra, MD, Ph.D., Prof. Raffaele Serra, University of Catanzaro |
ClinicalTrials.gov Identifier: | NCT02376998 |
Other Study ID Numbers: |
ERRATASTUDY |
First Posted: | March 3, 2015 Key Record Dates |
Results First Posted: | October 7, 2016 |
Last Update Posted: | October 7, 2016 |
Last Verified: | August 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Thoracic Aorta Trauma Endovascular |
Rupture Wounds and Injuries |